Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XNW5004 in Relapsed or Refractory Follicular Lymphoma (EZH2 Wild-type)
NCT07545603Phase 2Recruiting
- Sponsor
- Evopoint Biosciences
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of igermetostat in follicular lymphoma (FL), sponsored by Evopoint Biosciences. Started Feb 2026; status: recruiting.
02
Drugs
igermetostat
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT07545603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07545603.